{"id":16851,"date":"2026-04-27T13:20:06","date_gmt":"2026-04-27T13:20:06","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=case-study&#038;p=16851"},"modified":"2026-04-29T13:45:00","modified_gmt":"2026-04-29T13:45:00","slug":"antibody-drug-conjugate-production-workflow","status":"publish","type":"case-study","link":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/","title":{"rendered":"Antibody Drug Conjugate Production Workflow"},"content":{"rendered":"\n<h2 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-lg-font-size wp-elements-8ffc1b4040f9d6f8dabb729623451768\">In this case study we demonstrate Sygnature Discovery\u2019s ability to provide a complete, end\u2011to\u2011end Antibody Drug Conjugate (ADC) workflow to support client projects. In particular, we highlight the results of site specific and stochastic conjugation methods that were used.<\/h2>\n\n\n\n<p>At Sygnature Discovery, we can combine our in-house protein production expertise with specialist conjugation chemistries, and robust analytical characterisation to deliver high quality ADCs for clients.<\/p>\n\n\n\n<p>In a recent project we generated a panel of trastuzumab based ADCs incorporating several novel linker payload constructs. The project delivered five high\u2011quality ADCs using a combination of site specific and stochastic conjugation chemistries, we established new capabilities, workflows and analytical methods that enhance our ability to provide the entire ADC production workflow in house.<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-2-xl-font-size wp-elements-7fbb76d485318a102fcf422525006a38\">Establishing Safe Handling of Cytotoxic Payloads<\/h3>\n\n\n\n<p>Prior to starting work with cytotoxic payloads, the team implemented a dedicated cytotoxic\u2011handling system which is an essential requirement for ADC payload chemistry. This includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A new Class II biosafety cabinet with safe\u2011change filtration<\/li>\n\n\n\n<li>A dedicated cytotoxic waste stream<\/li>\n\n\n\n<li>Strict PPE requirements, including double gloves with DMSO\u2011resistant outers<\/li>\n\n\n\n<li>Use of screw\u2011cap tubes only and full secondary containment during transfers<\/li>\n<\/ul>\n\n\n\n<p>This infrastructure now supports all future ADC projects at Sygnature Discovery.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-2-xl-font-size wp-elements-816b0bbcbe5b46fb73c58a114b304736\">Stochastic Conjugation<\/h2>\n\n\n\n<p>A common conjugation technique in ADC production, is stochastic (random) conjugation. Stochastic conjugation is widely used because it requires no antibody engineering and can be readily scaled. In this project, payloads were attached via reduced interchain disulfides (Figure 1). A major part of the project involved DAR calibration, varying TCEP concentration, payload excess, temperature and reaction time to achieve the desired ADC DAR species.<\/p>\n\n\n\n<figure data-wp-context='{\"imageId\":\"69f31c998f18e\"}' data-wp-interactive=\"core\/image\" data-wp-key=\"69f31c998f18e\" class=\"wp-block-image size-full is-resized is-style-rounded is-style-rounded--1 wp-lightbox-container\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"1016\" height=\"199\" data-wp-class--hide=\"state.isContentHidden\" data-wp-class--show=\"state.isContentVisible\" data-wp-init=\"callbacks.setButtonStyles\" data-wp-on--click=\"actions.showLightbox\" data-wp-on--load=\"callbacks.setButtonStyles\" data-wp-on-window--resize=\"callbacks.setButtonStyles\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-1-Mechanism-of-stochastic-disulfide-based-conjugation-3.webp\" alt=\"\" class=\"wp-image-16836\" style=\"aspect-ratio:5.105817174515235;width:1440px;height:auto\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-1-Mechanism-of-stochastic-disulfide-based-conjugation-3.webp 1016w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-1-Mechanism-of-stochastic-disulfide-based-conjugation-3-300x59.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-1-Mechanism-of-stochastic-disulfide-based-conjugation-3-768x150.webp 768w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-1-Mechanism-of-stochastic-disulfide-based-conjugation-3-640x125.webp 640w\" sizes=\"(max-width: 1016px) 100vw, 1016px\"><button class=\"lightbox-trigger\" type=\"button\" aria-haspopup=\"dialog\" aria-label=\"Agrandir\" data-wp-init=\"callbacks.initTriggerButton\" data-wp-on--click=\"actions.showLightbox\" data-wp-style--right=\"state.imageButtonRight\" data-wp-style--top=\"state.imageButtonTop\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"12\" height=\"12\" fill=\"none\" viewbox=\"0 0 12 12\">\n\t\t\t\t<path fill=\"#fff\" d=\"M2 0a2 2 0 0 0-2 2v2h1.5V2a.5.5 0 0 1 .5-.5h2V0H2Zm2 10.5H2a.5.5 0 0 1-.5-.5V8H0v2a2 2 0 0 0 2 2h2v-1.5ZM8 12v-1.5h2a.5.5 0 0 0 .5-.5V8H12v2a2 2 0 0 1-2 2H8Zm2-12a2 2 0 0 1 2 2v2h-1.5V2a.5.5 0 0 0-.5-.5H8V0h2Z\"><\/path>\n\t\t\t<\/svg>\n\t\t<\/button><figcaption class=\"wp-element-caption\"><strong>Figure 1:<\/strong> Mechanism of stochastic disulfide-based conjugation<\/figcaption><\/figure>\n\n\n\n<p>Conditions identified in the initial calibration served as a starting point for client specific payloads. By varying TCEP and payload equivalents, we achieved DAR4 and DAR8 ADCs with minimal additional optimisation. The method transferred well, enabling accurate detection of conjugation and rapid progression to scale up within days.<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-2-xl-font-size wp-elements-3f029af142c727ef6f259a2d5c8e5759\">Site-Specific Conjugation<\/h3>\n\n\n\n<p>Site\u2011specific conjugation via microbial transglutaminase (tGase) requires access to a specific glutamine residue (Q295 in trastuzumab). However, the native glycan at N297 sterically blocks the enzyme. To resolve this, we optimised PNGase F deglycosylation of trastuzumab to ensure a single homogeneous species was produced (Figure 2).<\/p>\n\n\n\n<figure data-wp-context='{\"imageId\":\"69f31c998fbfd\"}' data-wp-interactive=\"core\/image\" data-wp-key=\"69f31c998fbfd\" class=\"wp-block-image size-full is-style-rounded is-style-rounded--2 wp-lightbox-container\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"797\" height=\"590\" data-wp-class--hide=\"state.isContentHidden\" data-wp-class--show=\"state.isContentVisible\" data-wp-init=\"callbacks.setButtonStyles\" data-wp-on--click=\"actions.showLightbox\" data-wp-on--load=\"callbacks.setButtonStyles\" data-wp-on-window--resize=\"callbacks.setButtonStyles\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-2-Mass-spectrometry-analysis-of-trastuzumab-before-and-after-PNGase-F-treatment-2.webp\" alt=\"\" class=\"wp-image-16839\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-2-Mass-spectrometry-analysis-of-trastuzumab-before-and-after-PNGase-F-treatment-2.webp 797w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-2-Mass-spectrometry-analysis-of-trastuzumab-before-and-after-PNGase-F-treatment-2-300x222.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-2-Mass-spectrometry-analysis-of-trastuzumab-before-and-after-PNGase-F-treatment-2-768x569.webp 768w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-2-Mass-spectrometry-analysis-of-trastuzumab-before-and-after-PNGase-F-treatment-2-486x360.webp 486w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-2-Mass-spectrometry-analysis-of-trastuzumab-before-and-after-PNGase-F-treatment-2-640x474.webp 640w\" sizes=\"(max-width: 797px) 100vw, 797px\"><button class=\"lightbox-trigger\" type=\"button\" aria-haspopup=\"dialog\" aria-label=\"Agrandir\" data-wp-init=\"callbacks.initTriggerButton\" data-wp-on--click=\"actions.showLightbox\" data-wp-style--right=\"state.imageButtonRight\" data-wp-style--top=\"state.imageButtonTop\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"12\" height=\"12\" fill=\"none\" viewbox=\"0 0 12 12\">\n\t\t\t\t<path fill=\"#fff\" d=\"M2 0a2 2 0 0 0-2 2v2h1.5V2a.5.5 0 0 1 .5-.5h2V0H2Zm2 10.5H2a.5.5 0 0 1-.5-.5V8H0v2a2 2 0 0 0 2 2h2v-1.5ZM8 12v-1.5h2a.5.5 0 0 0 .5-.5V8H12v2a2 2 0 0 1-2 2H8Zm2-12a2 2 0 0 1 2 2v2h-1.5V2a.5.5 0 0 0-.5-.5H8V0h2Z\"><\/path>\n\t\t\t<\/svg>\n\t\t<\/button><figcaption class=\"wp-element-caption\">Figure 2: Mass spectrometry analysis of trastuzumab before and after PNGase F treatment<\/figcaption><\/figure>\n\n\n\n<p>Intact mass analysis of untreated trastuzumab (Pre\u2011PNGase F treatment, top panel) reveals multiple glycoforms, producing a heterogeneous cluster of peaks between ~147,900 \u2013148,800 Da. Following enzymatic deglycosylation with PNGase F (Post\u2011PNGase F treatment, bottom panel) the heterogeneous glycoform pattern is reduced into a single species at ~145,169 Da. This shift reflects successful removal of glycans and yields a more homogeneous antibody population with a defined mass, suitable for site specific conjugation.<\/p>\n\n\n\n<p>Using the optimised deglycosylation of trastuzumab protocol, tGase conjugation proceeded efficiently, producing two uniform DAR2 ADCs with excellent analytical profiles. Mass spectrometry confirmed the expected single heavy\u2011chain modification pattern characteristic of tGase\u2011mediated site\u2011specific conjugation (Figure 3).<\/p>\n\n\n\n<figure data-wp-context='{\"imageId\":\"69f31c9990452\"}' data-wp-interactive=\"core\/image\" data-wp-key=\"69f31c9990452\" class=\"wp-block-image size-full is-style-rounded is-style-rounded--3 wp-lightbox-container\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"854\" height=\"568\" data-wp-class--hide=\"state.isContentHidden\" data-wp-class--show=\"state.isContentVisible\" data-wp-init=\"callbacks.setButtonStyles\" data-wp-on--click=\"actions.showLightbox\" data-wp-on--load=\"callbacks.setButtonStyles\" data-wp-on-window--resize=\"callbacks.setButtonStyles\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-3-Mass-spectrometry-analysis-of-a-site-specific-conjugated-trastuzumab-ADC-2.webp\" alt=\"\" class=\"wp-image-16841\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-3-Mass-spectrometry-analysis-of-a-site-specific-conjugated-trastuzumab-ADC-2.webp 854w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-3-Mass-spectrometry-analysis-of-a-site-specific-conjugated-trastuzumab-ADC-2-300x200.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-3-Mass-spectrometry-analysis-of-a-site-specific-conjugated-trastuzumab-ADC-2-768x511.webp 768w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-3-Mass-spectrometry-analysis-of-a-site-specific-conjugated-trastuzumab-ADC-2-541x360.webp 541w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-3-Mass-spectrometry-analysis-of-a-site-specific-conjugated-trastuzumab-ADC-2-640x426.webp 640w\" sizes=\"(max-width: 854px) 100vw, 854px\"><button class=\"lightbox-trigger\" type=\"button\" aria-haspopup=\"dialog\" aria-label=\"Agrandir\" data-wp-init=\"callbacks.initTriggerButton\" data-wp-on--click=\"actions.showLightbox\" data-wp-style--right=\"state.imageButtonRight\" data-wp-style--top=\"state.imageButtonTop\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"12\" height=\"12\" fill=\"none\" viewbox=\"0 0 12 12\">\n\t\t\t\t<path fill=\"#fff\" d=\"M2 0a2 2 0 0 0-2 2v2h1.5V2a.5.5 0 0 1 .5-.5h2V0H2Zm2 10.5H2a.5.5 0 0 1-.5-.5V8H0v2a2 2 0 0 0 2 2h2v-1.5ZM8 12v-1.5h2a.5.5 0 0 0 .5-.5V8H12v2a2 2 0 0 1-2 2H8Zm2-12a2 2 0 0 1 2 2v2h-1.5V2a.5.5 0 0 0-.5-.5H8V0h2Z\"><\/path>\n\t\t\t<\/svg>\n\t\t<\/button><figcaption class=\"wp-element-caption\"><strong>Figure 3:<\/strong> Mass spectrometry analysis of a site specific conjugated trastuzumab ADC<\/figcaption><\/figure>\n\n\n\n<p>Intact mass analysis of the light chain (top panel) shows a single peak at 23,442.7 Da, corresponding to the unmodified light chain (LC). This confirms that no payload is attached at the LC chain, consistent with the expected tGase mediated site\u2011specific conjugation chemistry, which targets a glutamine residue located on the heavy chain only.<\/p>\n\n\n\n<p>The heavy chain spectrum (bottom panel) displays one species at 49,525.1 Da, representing a +1 payload addition. This demonstrates efficient, site\u2011specific incorporation of a single linker payload molecule per heavy chain (HC), giving the characteristic DAR2 ADC (one payload on each of the two HC subunits). Together, these spectra confirm successful site\u2011specific conjugation, high reaction fidelity, and the expected uniform DAR2 species for the engineered ADC.<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-2-xl-font-size wp-elements-ab53838876460333b485231535d111bb\">Quality Control (QC)<\/h3>\n\n\n\n<p>To confirm ADC integrity, QC for all ADCs (Figure 4) produced includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>SEC-HPLC<\/li>\n\n\n\n<li>Mass spectrometry<\/li>\n\n\n\n<li>SDS-PAGE<\/li>\n\n\n\n<li>A280\/BCA concentration determination<\/li>\n<\/ul>\n\n\n\n<figure data-wp-context='{\"imageId\":\"69f31c9990eb8\"}' data-wp-interactive=\"core\/image\" data-wp-key=\"69f31c9990eb8\" class=\"wp-block-image size-large is-style-rounded is-style-rounded--4 wp-lightbox-container\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"827\" data-wp-class--hide=\"state.isContentHidden\" data-wp-class--show=\"state.isContentVisible\" data-wp-init=\"callbacks.setButtonStyles\" data-wp-on--click=\"actions.showLightbox\" data-wp-on--load=\"callbacks.setButtonStyles\" data-wp-on-window--resize=\"callbacks.setButtonStyles\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-4-QC-data-for-one-of-the-ADCs-produced-1-1024x827.webp\" alt=\"QC data for one of the ADCs produced\" class=\"wp-image-16834\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-4-QC-data-for-one-of-the-ADCs-produced-1-1024x827.webp 1024w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-4-QC-data-for-one-of-the-ADCs-produced-1-300x242.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-4-QC-data-for-one-of-the-ADCs-produced-1-768x620.webp 768w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-4-QC-data-for-one-of-the-ADCs-produced-1-1338x1080.webp 1338w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-4-QC-data-for-one-of-the-ADCs-produced-1-446x360.webp 446w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-4-QC-data-for-one-of-the-ADCs-produced-1-640x517.webp 640w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/04\/Figure-4-QC-data-for-one-of-the-ADCs-produced-1.webp 1354w\" sizes=\"(max-width: 1024px) 100vw, 1024px\"><button class=\"lightbox-trigger\" type=\"button\" aria-haspopup=\"dialog\" aria-label=\"Agrandir\" data-wp-init=\"callbacks.initTriggerButton\" data-wp-on--click=\"actions.showLightbox\" data-wp-style--right=\"state.imageButtonRight\" data-wp-style--top=\"state.imageButtonTop\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"12\" height=\"12\" fill=\"none\" viewbox=\"0 0 12 12\">\n\t\t\t\t<path fill=\"#fff\" d=\"M2 0a2 2 0 0 0-2 2v2h1.5V2a.5.5 0 0 1 .5-.5h2V0H2Zm2 10.5H2a.5.5 0 0 1-.5-.5V8H0v2a2 2 0 0 0 2 2h2v-1.5ZM8 12v-1.5h2a.5.5 0 0 0 .5-.5V8H12v2a2 2 0 0 1-2 2H8Zm2-12a2 2 0 0 1 2 2v2h-1.5V2a.5.5 0 0 0-.5-.5H8V0h2Z\"><\/path>\n\t\t\t<\/svg>\n\t\t<\/button><figcaption class=\"wp-element-caption\">Figure 4: QC data for one of the ADCs produced<\/figcaption><\/figure>\n\n\n\n<p><strong>A.<\/strong> SEC\u2011HPLC chromatograms confirm monodisperse ADCs with minimal aggregation. <br><strong>B.<\/strong> Intact MS outputs verify expected LC\/HC masses and correct DAR assignment. <br><strong>C.<\/strong> SDS\u2011PAGE shows the ADC under both reduced and non\u2011reduced conditions. <br><strong>D.<\/strong> BCA measurements provide accurate concentration assessment. Collectively, these QC data confirm the identity, purity and suitability of ADCs for downstream biological studies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-2-xl-font-size wp-elements-0df5e404bca9825ef00e1bb5a237a744\">Delivering High Quality ADCs for Client Research<\/h3>\n\n\n\n<p>Across all five ADCs generated in this project, our team delivered high purity ADCs suitable for downstream biological assays, supported by comprehensive analytical characterisation including accurate DAR determination, SEC\u2011HPLC, mass spectrometry, SDS\u2011PAGE, and A280\/BCA concentration measurements. These ADCs were produced at milligram scale quantities, enabling clients to progress confidently into early discovery studies.<\/p>\n\n\n\n<p>This work also demonstrated several core strengths within Sygnature\u2019s Protein Science team:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>An accurate and robust mass spectrometry workflow for robust DAR assignment<\/li>\n\n\n\n<li>Expertise in both stochastic and site specific conjugation<\/li>\n\n\n\n<li>End\u2011to\u2011end ADC production, from in house antibody expression through to conjugation and purification<\/li>\n\n\n\n<li>Troubleshooting of challenging payload chemistries<\/li>\n\n\n\n<li>SEC purification of ADCs for complete free payload removal<\/li>\n<\/ul>\n\n\n\n<p>Together, these capabilities now complement and enhance our established strengths in protein expression, purification, chemical biology and bioassay support, creating a comprehensive platform to accelerate client ADC programmes. In addition, through Sygnature Discovery\u2019s fully integrated discovery model, spanning medicinal chemistry for linker and payload design, bioscience, DMPK and in vivo pharmacology, we can deliver the entire ADC workflow in house, enabling seamless, cross disciplinary project execution and supporting complex, multi\u2011component ADC programmes from concept to candidate.<\/p>\n\n\n\n<h2 class=\"wp-block-heading has-dark-blue-500-color has-text-color has-link-color has-text-2-xl-font-size wp-elements-6029807ac9f9c86a1765af7e7b560bc0\">Conclusion<\/h2>\n\n\n\n<p>ADCs represent some of the most complex biologics in development today, sitting at the interface of protein science, synthetic chemistry and analytical characterisation. This project showcased the breadth of Sygnature Discovery\u2019s integrated capabilities, taking a therapeutic antibody from in house production through two conjugation strategies, multiple novel payloads, and full QC.<\/p>\n\n\n\n<p>Through this work, Sygnature Discovery is now able to offer a complete, end\u2011to\u2011end ADC workflow, fully customised to each client\u2019s payload chemistry, conjugation strategy and target DAR species. By optimising our intact mass spectrometry workflow, we can now resolve and quantify DAR species with minimal sample requirements, rapid turnaround times and high reproducibility, enabling confident decision making throughout ADC optimisation. Moreover, we can achieve a broad range of DAR species via both stochastic and site-specific conjugation, applying diverse linker payload systems to meet programme specific needs.<\/p>\n\n\n\n<p>Whether clients require early proof\u2011of\u2011concept ADCs, high DAR exploration, method development or tailored conjugation strategies, our multidisciplinary team is equipped to accelerate discovery programmes and support the development of next\u2011generation ADC therapeutics.<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-446b624a wp-block-columns-is-layout-flex\" style=\"padding-top:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50)\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"border-style:none;border-width:0px;border-top-left-radius:14px;border-top-right-radius:14px;border-bottom-left-radius:14px;border-bottom-right-radius:14px;padding-top:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50)\">\n<h2 class=\"wp-block-heading has-blue-400-color has-text-color has-link-color has-text-3-xl-font-size wp-elements-d22e8df867c526999e38d96fde857e5c\">Find out more about our unique approach to  Antibody Drug Conjugates<\/h2>\n<\/div>\n\n\n\n<div class=\"wp-block-column has-ivory-000-background-color has-background is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-top:var(--wp--preset--spacing--50);padding-right:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50);padding-left:var(--wp--preset--spacing--50)\">\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-f7b5deab wp-block-group-is-layout-flex\" style=\"padding-bottom:var(--wp--preset--spacing--30)\" allowchildrentofillwidth=\"\" overflow=\"\" flexwrap=\"\">\n<div class=\"wp-block-group overflow-hidden has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\" style=\"border-radius:24px\" allowchildrentofillwidth=\"\" overflow=\"hidden\" flexwrap=\"\"><section x-data=\"PegasusMediaBlock\" class=\"Media full-width w-full\" style=\"\">\n            \n                                    <picture><source srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/01\/ADC-300x186.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/01\/ADC.webp 517w\" sizes=\"(min-width: 1536px) 1536px, (min-width: 1280px) 1280px, (min-width: 1024px) 1024px, (min-width: 768px) 768px, (min-width: 640px) 640px, 100vw\" type=\"image\/webp\"><img decoding=\"async\" width=\"100%\" height=\"auto\" class=\"image-original \" alt=\"Antibody Drug Conjugates\" loading=\"eager\" sizes=\"(min-width: 1536px) 1536px, (min-width: 1280px) 1280px, (min-width: 1024px) 1024px, (min-width: 768px) 768px, (min-width: 640px) 640px, 100vw\" src=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/01\/ADC.jpg\" srcset=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/01\/ADC-300x186.webp 300w, https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/01\/ADC.webp 517w\"><\/source><\/picture>\n\n                \n            <\/section><\/div>\n\n\n\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-fe9cc265 wp-block-group-is-layout-flex\" allowchildrentofillwidth=\"\" overflow=\"\" flexwrap=\"\">\n<h3 class=\"wp-block-heading has-text-color has-link-color has-text-2-xl-font-size wp-elements-5438fcd1f08aeda4b9a59dc0d29a8d3e\" style=\"color:#002b46;margin-bottom:var(--wp--preset--spacing--20)\"><a href=\"https:\/\/www.sygnaturediscovery.com\/fr\/modalites\/conjugues-de-medicaments-anticorps-adc\/\">conjugu\u00e9s anticorps-m\u00e9dicament<\/a><\/h3>\n\n\n\n<p class=\"has-text-color has-link-color has-text-base-font-size wp-elements-5d14f383961f0354aae0505fecb0d093\" style=\"color:#001024b3;margin-bottom:var(--wp--preset--spacing--20)\">D\u00e9couvrez plus en d\u00e9tail notre large \u00e9ventail de capacit\u00e9s pour soutenir les projets ADC.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-text-link\" modaltype=\"\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/modalites\/conjugues-de-medicaments-anticorps-adc\/\">Apprendre encore plus<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":8039,"template":"","category":[744,769],"resource_tag":[],"class_list":["post-16851","case-study","type-case-study","status-publish","has-post-thumbnail","hentry","category-adcs","category-antibodies-and-biotherapeutics"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Antibody Drug Conjugate Production Workflow - Sygnature<\/title>\n<meta name=\"description\" content=\"In this case study we demonstrate Sygnature Discovery\u2019s ability to provide a complete, end to end Antibody Drug Conjugate Production Workflow (ADC) workflow to support client projects\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibody Drug Conjugate Production Workflow - Sygnature\" \/>\n<meta property=\"og:description\" content=\"In this case study we demonstrate Sygnature Discovery\u2019s ability to provide a complete, end to end Antibody Drug Conjugate Production Workflow (ADC) workflow to support client projects\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-29T13:45:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/12\/multimodal-drug-discovery-protacs-molecular-glues-biologics.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1065\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/antibody-drug-conjugate-production-workflow\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/antibody-drug-conjugate-production-workflow\\\/\",\"name\":\"Antibody Drug Conjugate Production Workflow - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/antibody-drug-conjugate-production-workflow\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/antibody-drug-conjugate-production-workflow\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/multimodal-drug-discovery-protacs-molecular-glues-biologics.webp\",\"datePublished\":\"2026-04-27T13:20:06+00:00\",\"dateModified\":\"2026-04-29T13:45:00+00:00\",\"description\":\"In this case study we demonstrate Sygnature Discovery\u2019s ability to provide a complete, end to end Antibody Drug Conjugate Production Workflow (ADC) workflow to support client projects\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/antibody-drug-conjugate-production-workflow\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/antibody-drug-conjugate-production-workflow\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/antibody-drug-conjugate-production-workflow\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/multimodal-drug-discovery-protacs-molecular-glues-biologics.webp\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/multimodal-drug-discovery-protacs-molecular-glues-biologics.webp\",\"width\":1065,\"height\":600,\"caption\":\"3D molecular visualization representing diverse therapeutic modalities in drug discovery, including PROTACs, molecular glues, peptides, and RNA-targeting therapies.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/case-study\\\/antibody-drug-conjugate-production-workflow\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibody Drug Conjugate Production Workflow\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antibody Drug Conjugate Production Workflow - Sygnature","description":"In this case study we demonstrate Sygnature Discovery\u2019s ability to provide a complete, end to end Antibody Drug Conjugate Production Workflow (ADC) workflow to support client projects","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/","og_locale":"fr_CA","og_type":"article","og_title":"Antibody Drug Conjugate Production Workflow - Sygnature","og_description":"In this case study we demonstrate Sygnature Discovery\u2019s ability to provide a complete, end to end Antibody Drug Conjugate Production Workflow (ADC) workflow to support client projects","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/","og_site_name":"Sygnature","article_modified_time":"2026-04-29T13:45:00+00:00","og_image":[{"width":1065,"height":600,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/12\/multimodal-drug-discovery-protacs-molecular-glues-biologics.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/","name":"Antibody Drug Conjugate Production Workflow - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/12\/multimodal-drug-discovery-protacs-molecular-glues-biologics.webp","datePublished":"2026-04-27T13:20:06+00:00","dateModified":"2026-04-29T13:45:00+00:00","description":"In this case study we demonstrate Sygnature Discovery\u2019s ability to provide a complete, end to end Antibody Drug Conjugate Production Workflow (ADC) workflow to support client projects","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/12\/multimodal-drug-discovery-protacs-molecular-glues-biologics.webp","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/12\/multimodal-drug-discovery-protacs-molecular-glues-biologics.webp","width":1065,"height":600,"caption":"3D molecular visualization representing diverse therapeutic modalities in drug discovery, including PROTACs, molecular glues, peptides, and RNA-targeting therapies."},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/case-study\/antibody-drug-conjugate-production-workflow\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Antibody Drug Conjugate Production Workflow"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/16851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/case-study"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/case-study\/16851\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/8039"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=16851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=16851"},{"taxonomy":"resource_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/resource_tag?post=16851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}